NEW YORK - Amwell (NYSE: AMWL), a company specializing in digital healthcare solutions, has announced plans to release its fourth quarter financial results for 2023 on Wednesday, February 14. Following the release, which will be distributed through wire services, Amwell's management will conduct a live conference call and webcast at 5 p.m. Eastern Time to discuss the operating outcomes and provide a business update.
Investors and interested parties will have the opportunity to join the conference call by dialing (888) 510-2008 within the United States or (646) 960-0306 internationally, with the call ID number 7830032. Additionally, the webcast can be accessed through the Investors section of Amwell's website.
A replay of the webcast will be available on the company's investor relations website, investors.amwell.com, for approximately 90 days following the event.
Amwell, recognized as a leading platform for hybrid care delivery, facilitates connections between providers, insurers, patients, and innovators, aiming to improve access to quality healthcare while managing costs. The company's platform supports a range of digital health needs, from urgent to post-acute care, including chronic care management and promoting healthy living.
With nearly two decades of experience in the industry, Amwell's services are utilized by over 55 health plans, which represent more than 90 million covered lives. Additionally, it collaborates with some of the nation's largest health systems, encompassing over 2,000 hospitals.
This forthcoming earnings report and conference call will be closely watched by investors and industry analysts as an indicator of Amwell's performance and strategic direction in the evolving field of digital healthcare.
The information for this article is based on a press release statement from Amwell.
InvestingPro Insights
As Amwell (NYSE: AMWL) prepares to unveil its Q4 2023 financial results, investors are closely monitoring the company's metrics and market performance. According to InvestingPro data, Amwell has a market capitalization of $316.33M and holds a negative P/E ratio of -0.45, reflecting challenges in profitability. The company's revenue for the last twelve months as of Q3 2023 stands at $267.6M, with a gross profit margin of 39.05%. However, it's notable that the company has experienced a revenue decline of 1.15% during the same period.
InvestingPro Tips suggest that while Amwell holds more cash than debt on its balance sheet, it is quickly burning through cash. Analysts have revised their earnings upwards for the upcoming period, yet they do not anticipate the company will be profitable this year. Additionally, Amwell's stock has suffered declines over various timeframes, with a 26.17% drop over the last month and a significant 72.29% fall over the last year.
For investors seeking deeper insights, InvestingPro offers additional tips on Amwell's financial health and prospects. With a special New Year sale, a subscription to InvestingPro is now available with up to a 50% discount. Use coupon code SFY24 to get an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 to get an additional 10% off a 1-year subscription. Currently, there are 9 more InvestingPro Tips available for Amwell, which could provide valuable guidance to investors looking to make informed decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.